Pharma & Biotech Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit By Ian Lyall 02/09
Pharma & Biotech Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials By Ian Lyall 02/09
Pharma & Biotech Ondine Biomedical share price rallies following 40% drop in surgical infections By Ian Lyall 01/09
Pharma & Biotech Futura Medical advances Eroxon pipeline as it reshapes US commercial strategy By Ian Lyall 01/09
Pharma & Biotech GENinCode shares rise over 18% intraday after coronary disease test results presented at European conference By Ian Lyall 28/08
Pharma & Biotech Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris By Ian Lyall 28/08
Pharma & Biotech GLP-1 maker hit with 'sell' rating as 2027 revenue cliff fears mount By Ian Lyall 27/08
Pharma & Biotech Stifel reiterates Buy on Faron Pharmaceuticals after cash update secures runway to key trial readout By Ian Lyall 26/08
Pharma & Biotech HaemaLogiX advances KOALA blood cancer trial after safely dosing first patient By Ian Lyall 26/08
Pharma & Biotech Faron targets second-half start for pivotal blood cancer trial after latest investment round By Ian Lyall 26/08
Health Vivace Therapeutics names new CEO as it prepares Phase 3 trial for mesothelioma drug By Proactive 26/08
Pharma & Biotech UBS cuts Smith & Nephew target on competitive threats to three franchises By Ian Lyall 25/08
